



Cite this: *Chem. Commun.*, 2016, 52, 11603

## Correction: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies

Stacey E. Rudd,<sup>a</sup> Peter Roselt,<sup>b</sup> Carleen Cullinane,<sup>bc</sup> Rodney J. Hicks<sup>\*cd</sup> and Paul S. Donnelly<sup>\*a</sup>

DOI: 10.1039/c6cc90413k

[www.rsc.org/chemcomm](http://www.rsc.org/chemcomm)

Correction for 'A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies' by Stacey E. Rudd *et al.*, *Chem. Commun.*, 2016, DOI: 10.1039/c6cc05961a.

The authors regret that a significant reference was omitted from the original article. A citation to work by Gasser, Mindt and co-workers should have been included in the first page.

"The addition of an extra hydroxamic acid functional group to give an octadentate variant called DFO\* resulted in improved stability of <sup>89</sup>Zr<sup>IV</sup> complexes but the ligand suffers from limited solubility in aqueous environments.<sup>1</sup>"

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

### References

- 1 M. Patra, A. Baumann, C. Mari, C. A. Fischer, O. Blacque, D. Häussinger, G. Gasser and T. L. Mindt, *Chem. Commun.*, 2014, **50**, 11523–11525.

<sup>a</sup> School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, 3010, Australia. E-mail: pauld@unimelb.edu.au

<sup>b</sup> Research Division, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne 3000, Victoria, Australia

<sup>c</sup> The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. E-mail: Rod.Hicks@petermac.org

<sup>d</sup> Centre for Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne 3000, Victoria, Australia

